Human EGFR-T790M/C797S/L858R Stable Cell Line - NCI-H1975

Epidermal growth factor receptor (EGFR) is a protein found on the surface of certain cells and plays a key role in cell growth and survival. When a molecule called a ligand binds to EGFR, it triggers a series of cellular events that promote cell growth and division. This binding stimulates the intrinsic protein tyrosine kinase activity of the receptor, resulting in autophosphorylation of several tyrosine residues in the C-terminal domain. EGFR-T790M/C797S/L858R refers to three specific mutations in the epidermal growth factor receptor (EGFR) gene. These mutations are often associated with non-small cell lung cancer. The EGFR-T790M mutation is often referred to as a “gatekeeper” mutation because of its role in the development of resistance to first- and second-generation tyrosine kinase inhibitors (TKIs), a common treatment for lung cancer. This mutation changes the structure of EGFR, thereby reducing the drug's ability to bind to and inhibit the receptor. The EGFR-C797S mutation often occurs after treatment with third-generation TKIs, leading to resistance to these drugs. The C797S mutation changes the shape of the EGFR protein and reduces the efficacy of TKIs. EGFR-L858R mutation is a common EGFR activating mutation. It makes cells more likely to grow and divide in an uncontrolled manner, which often leads to the development of cancer. Human EGFR-T790M/C797S/L858R Stable Cell Line - NCI-H1975 is a unique form of cell line genetically engineered to express three specific mutations in the epidermal growth factor receptor (EGFR) gene. Derived from the NCI-H1975 human lung adenocarcinoma cell line, this cell line provides an exciting tool for researchers seeking to explore the complex dynamics of lung cancer pathology, drug resistance, and potential targeted therapies.